RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Matinas BioPharma Holdings P/S 2024

Matinas BioPharma Holdings P/S

0

Matinas BioPharma Holdings Dividend yield

Ticker

MTNB

ISIN

US5768101058

WKN

A2DMQP

As of May 30, 2024, Matinas BioPharma Holdings's P/S ratio stood at 0, a 0% change from the 77.83 P/S ratio recorded in the previous year.

The Matinas BioPharma Holdings P/S history

Matinas BioPharma Holdings Aktienanalyse

What does Matinas BioPharma Holdings do?

Matinas BioPharma Holdings Inc is a biopharmaceutical company focused on the development of novel lipid-based therapies for patients with serious illnesses. The company was founded in 2013 and is headquartered in Bedminster, New Jersey. Its history dates back to the development of a novel lipid nanoparticle technology that enables safer and more effective delivery and targeted release of therapeutic agents in the body. Matinas BioPharma has two divisions, one dedicated to the research and development of prescription drugs for the treatment of infectious diseases and the other focused on the development of lipid-based dietary supplements for health improvement. One of its notable products is the antimicrobial therapeutic MAT 2203, which has been successfully tested in clinical Phase II and is used as an oral treatment for patients with severe and potentially life-threatening fungal infections. Overall, Matinas BioPharma is an innovator in lipid-based drug development, offering promising potential for the improvement of patient health through its technology and strategic partnerships. Matinas BioPharma Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Matinas BioPharma Holdings's P/S Ratio

Matinas BioPharma Holdings's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Matinas BioPharma Holdings's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Matinas BioPharma Holdings's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Matinas BioPharma Holdings’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Matinas BioPharma Holdings Stock

What is the price-to-earnings ratio of Matinas BioPharma Holdings?

The price-earnings ratio of Matinas BioPharma Holdings is currently 0.

How has the price-earnings ratio of Matinas BioPharma Holdings changed compared to last year?

The price-to-earnings ratio of Matinas BioPharma Holdings has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Matinas BioPharma Holdings high compared to other companies?

Yes, the price-to-earnings ratio of Matinas BioPharma Holdings is high compared to other companies.

How does an increase in the price-earnings ratio of Matinas BioPharma Holdings affect the company?

An increase in the price-earnings ratio of Matinas BioPharma Holdings would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Matinas BioPharma Holdings affect the company?

A decrease in the price-earnings ratio of Matinas BioPharma Holdings would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Matinas BioPharma Holdings?

Some factors that influence the price-earnings ratio of Matinas BioPharma Holdings are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Matinas BioPharma Holdings pay?

Over the past 12 months, Matinas BioPharma Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Matinas BioPharma Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Matinas BioPharma Holdings?

The current dividend yield of Matinas BioPharma Holdings is .

When does Matinas BioPharma Holdings pay dividends?

Matinas BioPharma Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Matinas BioPharma Holdings?

Matinas BioPharma Holdings paid dividends every year for the past 0 years.

What is the dividend of Matinas BioPharma Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Matinas BioPharma Holdings located?

Matinas BioPharma Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Matinas BioPharma Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Matinas BioPharma Holdings from 5/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.

When did Matinas BioPharma Holdings pay the last dividend?

The last dividend was paid out on 5/30/2024.

What was the dividend of Matinas BioPharma Holdings in the year 2023?

In the year 2023, Matinas BioPharma Holdings distributed 0 USD as dividends.

In which currency does Matinas BioPharma Holdings pay out the dividend?

The dividends of Matinas BioPharma Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Matinas BioPharma Holdings

Our stock analysis for Matinas BioPharma Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Matinas BioPharma Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.